FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation ...

FDA approves at-home subcutaneous self-injection initiation for lecanemab (Alzheimer's monoclonal antibody), replacing intravenous infusion clinic visits with 500 mg weekly doses via two 250 mg injections for early disease. This is the first subcutaneous starting option for anti-amyloid AD treatment, removing a major treatment access barrier.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.